Medipost Reports 3rd Quarter Revenue of 57.5 Billion Won Amid Increased Costs for Cartistem Commercialization

Medipost reported a revenue of 57.5 billion won for the third quarter of this year. However, profitability declined due to rising clinical costs associated with the commercialization of its knee osteoarthritis stem cell treatment, Cartistem, in the United States and Japan.


The company announced on November 16 that its consolidated revenue for the third quarter reached 57.5 billion won, a 3.1% increase compared to the same period last year. During the same period, it recorded an operating loss of 61 billion won. On a standalone basis, revenue was 61.5 billion won, with an operating loss of 800 million won.


The losses were attributed to increased overseas clinical expenses. In the U.S., patient dosing for the Phase 3 trial of Cartistem has led to significant spending on ongoing research and development. In Japan, the company is preparing data for regulatory submission following the completion of its Phase 3 trial. Medipost explained that this increase in costs is a strategic investment aimed at securing a leading position in the global market.


A Medipost official stated, "The third quarter consolidated results reflect substantial costs for key clinical trials and regulatory preparations for Cartistem's commercialization in the U.S. and Japan. We aim to complete the Phase 3 dosing in the U.S. and the regulatory submission in Japan without delays to enhance corporate and shareholder value."


The company has also restructured its management. Medipost appointed Min Ho-sung as the new CEO in the third quarter. CEO Min will oversee global operations, including U.S. and Japanese subsidiaries, overseas clinical trials, and business development in key regions, with an emphasis on strengthening responsibility management by area.


Medipost plans to release interim results of real-world evidence (RWE) for Cartistem by the end of the year and announce future development plans for SMUP-IA-01.





* This article has been translated by AI.